Maartje J. Hooning

Maartje J. Hooning is a senior scientist and group leader in the Department of Medical Oncology at Erasmus University Medical Center, Rotterdam. She leads the Cancer Epidemiology research group, focusing on hereditary breast/ovarian cancer and late effects of cancer treatment.

• MD from University of Amsterdam (1990)
• MSc in Clinical Epidemiology
• PhD in Cancer Epidemiology (Netherlands Cancer Institute)

Her research integrates genetic, hormonal/lifestyle, and treatment data to build risk/prognostic models for high-risk families. Current projects include:

• CHEK2: Risk prediction for CHEK2 c.1100delC families
• HARMONY: Long-term effects of premenopausal risk-reducing salpingo-oophorectomy
• B2B: Online decision aid for contralateral breast cancer risk
• PREVOM: Impact of bilateral mastectomy on survival and anxiety in BRCA1/2 carriers

Her work is supported by national collaborations (HEBON, Netherlands Cancer Institute, Radboud UMC) and international consortia (BCAC, CIMBA). Key articles highlight trends in:

• 2022: Chemotherapy effects on contralateral breast cancer risk
• 2021: Hormonal therapy in triple-negative breast cancer
• 2020: Polygenic risk scoring for contralateral cancer
• 2019: Survival outcomes after bilateral mastectomy

She has supervised multiple PhD students and secured grants from KWF, Pink Ribbon, Alpe d’HuZes, and NWO for projects like the HARMONY study and CHEK2 research. Her team collaborates with Clinical Genetics, Pathology, Radiology, and Gynecological Oncology at Erasmus MC, alongside national and international partners.